REGENERON PHARMACEUTICALS, INC.
REGN US75886F1075
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 31% | 15% | 22% | -21% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Mccourt Marion EX VP |
844.61 USD |
1,000 Sold |
844,610 USD |
01/11/2024 | 01/11/2024 |
| Ryan Arthur F |
1,051.51 USD |
9 Sold |
9,464 USD |
01/10/2024 | 01/10/2024 |
| Ryan Arthur F |
1,057.38 USD |
2 Sold |
2,115 USD |
01/10/2024 | 01/10/2024 |
| Ryan Arthur F |
1,052.44 USD |
4 Sold |
4,210 USD |
01/10/2024 | 01/10/2024 |
| Ryan Arthur F |
1,059.28 USD |
2 Sold |
2,119 USD |
01/10/2024 | 01/10/2024 |
| Ryan Arthur F |
1,056.68 USD |
3 Sold |
3,170 USD |
01/10/2024 | 01/10/2024 |
| Ryan Arthur F |
1,054.90 USD |
3 Sold |
3,165 USD |
01/10/2024 | 01/10/2024 |
| Ryan Arthur F |
1,053.45 USD |
4 Sold |
4,214 USD |
01/10/2024 | 01/10/2024 |
| Ryan Arthur F |
1,047.44 USD |
12 Sold |
12,569 USD |
01/10/2024 | 01/10/2024 |
| Mccourt Marion EX VP |
1,054.06 USD |
1,000 Sold |
1,054,060 USD |
01/10/2024 | 01/10/2024 |